breast cancer	is a	malignant neoplasm
breast cancer	may metastasize to	bone
breast cancer	may metastasize to	liver
breast cancer	may metastasize to	lung
breast cancer	may metastasize to	brain
breast cancer	is associated with	estrogen receptor status
breast cancer	is associated with	HER2 status
breast cancer	is associated with	progesterone receptor status
breast cancer	is linked with	luminal subtype
breast cancer	is linked with	triple-negative subtype
breast cancer	associated with	BRCA mutation
BRCA mutation	increases	breast cancer risk
age	is risk factor for	breast cancer
family history	is risk factor for	breast cancer
diabetes	is risk factor for	breast cancer
obesity	is risk factor for	breast cancer
smoking	is risk factor for	breast cancer
alcohol use	is risk factor for	breast cancer
breast cancer	associated with	recurrence
breast cancer	associated with	mortality
breast cancer	associated with	readmission
breast cancer	associated with	metastasis
breast cancer	treated with	chemotherapy
breast cancer	treated with	radiotherapy
breast cancer	treated with	surgery
breast cancer	treated with	targeted therapy
breast cancer	treated with	hormonal therapy
tamoxifen	is a	selective estrogen receptor modulator
letrozole	is a	aromatase inhibitor
anastrozole	is a	aromatase inhibitor
trastuzumab	is a	monoclonal antibody
trastuzumab	treats	HER2 positive breast cancer
trastuzumab	causes	cardiotoxicity
bone metastasis	causes	bone pain
bone metastasis	leads to	fracture
liver metastasis	causes	hepatic failure
lung metastasis	causes	hypoxemia
brain metastasis	causes	neurological deficit
neutropenia	increases	infection risk
anemia	reduces	quality of life
thrombocytopenia	increases	bleeding risk
chemotherapy	causes	nausea
chemotherapy	causes	vomiting
chemotherapy	causes	fatigue
radiation therapy	causes	skin dermatitis
radiation therapy	causes	fatigue
surgery	reduces	tumor burden
lumpectomy	preserves	breast
mastectomy	removes	breast tissue
axillary lymph node dissection	removes	lymph nodes
sentinel lymph node biopsy	assesses	nodal status
nodal status	guides	adjuvant therapy
tumor size	correlates with	prognosis
tumor grade	correlates with	prognosis
estrogen receptor status	predicts	endocrine therapy response
HER2 status	predicts	trastuzumab response
BRCA mutation	predicts	PARP inhibitor eligibility
PARP inhibitor	treats	BRCA mutant breast cancer
PARP inhibitor	targets	BRCA mutated tumor
olaparib	is a	PARP inhibitor
immune checkpoint inhibitor	is used for	PD-L1 positive breast cancer
PD-L1 status	predicts	checkpoint inhibitor response
mammography	detects	breast cancer
MRI	evaluates	extent of disease
ultrasound	detects	mass
biopsy	confirms	cancer diagnosis
sentinel node	indicates	nodal involvement
nodal involvement	worsens	prognosis
radiotherapy	improves	local control
adjuvant chemotherapy	reduces	recurrence
neoadjuvant therapy	reduces	tumor size
clinical trial	offers	experimental therapy
breast cancer	increases	healthcare cost
cost of care	influences	treatment choice
insurance coverage	influences	access to therapy
access to therapy	affects	outcomes
comorbidity	influences	mortality
obesity	worsens	prognosis
diabetes	worsens	prognosis
hypertension	worsens	prognosis
smoking	worsens	prognosis
age	correlates with	mortality
age	correlates with	recurrence
menopausal status	influences	endocrine therapy eligibility
duration of therapy	affects	adherence
adherence	affects	treatment outcomes
radiotherapy	reduces	local recurrence
breast-conserving surgery	requires	clear margins
clear margins	indicate	tumor clearance
tumor-free margins	indicate	complete resection
tumor margins	predict	prognosis
receptor status	guides	therapy selection
tumor markers	correlate with	prognosis
HER2 overexpression	defines	aggressive disease
triple-negative breast cancer	lacks	hormone receptor expression
triple-negative breast cancer	lacks	HER2 expression
bone pain	indicates	bone metastasis
lymphatic invasion	associates with	metastasis
neoadjuvant chemotherapy	yields	pathological complete response
pathological complete response	predicts	long-term survival
